

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Nicosia et al.		
Serial No.:	09/463,098	Case No.:	IT0019P
Filed:	May 15, 2000		
For:	MIMOTOPES OF HYPERVARIABLE REGION 1 OF THE E2 GLYCOPROTEIN OF HCV AND USES THEREOF		

Art Unit: 1639  
Examiner: Wessendorf, Teresa D  
03 MAY 12 2010:31  
RECEIVED  
TECH CENTER 1600/2900

COMMUNICATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a marked-up copy of a substitute specification. Also enclosed is a copy of a post card listing a substitute specification along with a marked-up copy of the substitute specification as part of an October 26, 2001 submission. The marked-up copy shows changes made to the specification to insert sequence identifiers.

Please charge deposit account 13-2755 for fees due in connection with this communication. If any time extensions are needed for the timely filing of the present communication, applicants petition for such extensions and authorize the charging of deposit account 13-2755 for the appropriate fees.

Respectfully submitted,

By Sheldon O. Heber  
Sheldon O. Heber  
Reg. No. 38,179  
Attorney for Applicants  
Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-1958

In re the Application of : The following paper(s) has/have been received:

Alfredo Nicosia, et al. : Transmittal Sheet with Cert. of Mailing Under 37 CFR 1.8(a), Petition for one month extension of time; Computation of Fee (in duplicate)


Application Number: 94 Sheets of Substitute Specification  
09/463,098 94 Sheets of Marked up draft showing where sequence ID Nos. have been inserted

For: Mimotopes of Hypervariable Region 1 of the E2 Glycoprotein of HCV and : Copy of Notice to Comply  
Uses Thereof Check in the amount of \$110.00  
10 Sheets of Second Preliminary Amendment


Patent and Trademark Office is respectfully requested to place its STAMP on the POSTAL CARD and place it in the outgoing mail.

Mewburn  
10/26/01 jcb

Respectfully,  
KDR



RECEIVED  
10:32 AM  
JAN 12 2002  
TECH CENTER 1600  
03/01/02  
PATENT & TRADEMARK OFFICE




DANN DORFMAN HERRELL AND SKILLMAN  
A PROFESSIONAL CORPORATION  
SUITE 720  
1601 MARKET STREET  
PHILADELPHIA, PA 19103-2307

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Claims have not been amended to recite sequence ID. Nos.  
*(these must be included in the claims)*

### Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**